Navigation Links
ThromboGenics Announces Business Update and 2008 Full Year Results
Date:3/12/2009

LEUVEN, Belgium, March 12 /PRNewswire-FirstCall/ --

- ThromboGenics Reports Pre-Tax Profit of EUR12.2 Million For 2008

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments that will make a real difference to patient care in a number of important therapeutic areas, is today issuing a business update and its financial results for the full year ending December 31, 2008.

During the last twelve months, ThromboGenics has made considerable progress across all aspects of its business culminating in the recent start of the Phase III clinical development program for its lead product microplasmin in back of the eye disease. The decision to start the Phase III program was based on the positive Phase II clinical results which were announced over the course of 2008.

In June 2008, ThromboGenics announced a further important corporate milestone, the signing of a high value strategic alliance with Roche for its novel anti-cancer antibody TB-403 (anti-PIGF). This deal, which generated an upfront payment of EUR30 million, has provided significant funding to allow ThromboGenics to invest in its other development programs.

The upfront payment from the Roche deal has enabled ThromboGenics to report a pre-tax profit of EUR 12.2 million in 2008.

Given its recent progress, ThromboGenics is confident that over the next eighteen months it will be able to generate significant shareholder value as it continues to maximize the value of its exciting product pipeline.

Business Highlights

Clinical Highlights

Microplasmin - Eye Disease: Positive results announced in Phase II clinical trials for back of the eye indications. Positive results were reported in ThromboGenics' Phase IIb (MIVI III) trial in patients with a number of back of the eye conditions. The trial show
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
2. ThromboGenics N.V.: Business Update
3. ThromboGenics Announces Half Year Results 2008
4. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
5. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
6. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
7. ThromboGenics N.V. - Business Update
8. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
9. ThromboGenics Announces 2007 Full Year Results
10. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
11. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... (PRWEB) September 18, 2014 OMICS ... the globe to participate in the ‘Open Access ... articles to OMICS Group Pharma Journals ... one of the fastest emerging Sciences, accelerating with ... healthcare services across the globe. The industry is ...
(Date:9/18/2014)... September 18, 2014 SeqLL Inc., ... (tSMS™) technology, announced today the closing of a ... led by Genomic Diagnostic Technologies, will increase the ... applications. , Founded in March 2013 by Daniel ... Analyst at Helicos BioSciences, SeqLL has continued to ...
(Date:9/18/2014)... group of rare diseases that afflict skeletal growth ... hits at the fetal stage and is caused ... encoding fibroblast growth factor receptor 3 (FGFR3) has ... thanatophoric dysplasia (TD), a skeletal dysplasia that cause ... lethal, and achondroplasia (ACH), which causes stunted growth ...
(Date:9/18/2014)... can be pretty expensive. Now a team led by ... open-source library of designs that will let scientists slash ... the syringe pump. , Syringe pumps are used to ... or mixing chemicals in a reaction. They can also ... Pearce and his team of Michigan Tech students published ...
Breaking Biology Technology:Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Doing science just got cheaper -- and faster 2
... Inc., (TSX: IXS.V; OTC Bulletin Board: IXSBF),( http://www.ixsbio.com ... of monoclonal antibodies based on its Dynamic Cross ... a large scale,primate study of DXL625 (CD20), the ... study in cynomolgus monkeys of DXL625, an antibody,directed ...
... Odyssey Thera, Inc. announced,that it has received a ... progress a discovery stage drug candidate into,pre-clinical development. ... as part of the ongoing collaboration with Pfizer., ... of the collaboration with,Pfizer," said John K. Westwick, ...
... (OTC,Pink Sheets: AIMM) today reported a net loss of $86,000, ... ended June 30, 2008, compared with,a net loss of $62,000, ... months ended June 30, 2007. For the six months ended ... share basic and diluted, compared,with net loss of $54,000, or ...
Cached Biology Technology:InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625 2AutoImmune Inc. Reports 2008 Second Quarter Financial Results 2AutoImmune Inc. Reports 2008 Second Quarter Financial Results 3
(Date:9/17/2014)... affordable health care to reproductive technologies, the justice ... ability of people to identify key issues, articulate ... and find the most defensible ways forward. But ... these societal conversations?, The Hastings Center and the ... have teamed up to publish a series of ...
(Date:9/17/2014)... UT Arlington engineering professor and his doctoral student have ... can accumulate water collected from fog and dew., The ... world or deserts around the globe., Cheng Luo, professor ... Heng, PhD candidate in the same College of Engineering ... 25 edition of ACS, (American Chemical Society) ...
(Date:9/17/2014)... has developed, very cleverly, some lessons on how to ... said Joseph Shaw, director of the Optical Technology Center ... structures at the nanoscale, we,ll discover them." , Some ... August during a conference called "The Nature of Light: ... of the University of Arizona College of Optical Sciences. ...
Breaking Biology News(10 mins):Why bioethics literacy matters 2Why bioethics literacy matters 3Shorebird's beak inspires UT Arlington research on water collection 2Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3
... may not be the answer to mitigating climate change by ... to an international team of plant biologists. The researchers found ... fungi (AMF) -- a type of fungus that is often ... then leads to higher decomposition rates of organic materials, said ...
... the methane on Earth comes from the ocean,s oxygen-rich waters, ... this potent greenhouse gas. Now researchers report that they have ... the most abundant microbes on the planet. The findings ... who made the discovery did not set out to explain ...
... part of the marine ecosystem, fostering biodiversity and protecting ... with pollution and harmful fishing practices, are one of ... One of the solutions to the crisis ... Tel Aviv University,s Department of Molecular Microbiology and Biotechnology, ...
Cached Biology News:Plants' fungi allies may not help store climate change's extra carbon 2Study identifies prime source of ocean methane 2Study identifies prime source of ocean methane 3Viruses could be the key to healthy corals 2
... a simple high performance method for removing ... without significant dilution of protein solution. ... Detergent-OUT Spin column and collect detergent free ... removing detergent from a maximum of 0.2 ...
... Chemicon Detergent-OUT SDS Kit is a simple ... protein solutions. Removes detergents without significant ... the protein solution on the Detergent-OUT Spin ... Med columns are suitable for removing ...
... from frozen embedded tissue blocks, which are ... ensure the highest quality. Tissues of each ... sectioned at a thickness of 7 microns ... large (3-5 mm in diameter) in comparison ...
... Zyagen tissue microarrays are derived from frozen ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... coated slides. Sections are large (3-5mm in ...
Biology Products: